Ondine Biomedical Share Discussion Threads

[jailbird] 26/3/2024 12:36

How many hospitals and more importantly how many patients need to use Steriwave before the company becomes aProfitable business ?Current number is clearly not enough We need some revenue forecasts , or a broker research note , something to work on

[jailbird] 25/3/2024 15:52

OBI likes to talk about saving a hospital dept can make but mentions nothing about the value that it bring to the company

[jailbird] 25/3/2024 15:42

Maybe a big delayed sell in the background But it should reflect on L2 prices !!!

[jailbird] 25/3/2024 15:41

Crazy market Can buy at 10p!!!!Yet it is 2v1 on L2 WTF IS GOING ON , false pricing at present

[jailbird] 25/3/2024 15:39

I guess the question is , will the placing be above or below 9p this time It is a bit of a crazy situation to be raising again 5 months later Do not understand why the extra few million was just not raised at the last one Must be some deal made with the Instituitions who supported the last raise as they would know this was an interim funding

[luzley] 25/3/2024 11:44

A 20p share offer at this stage is fair and realistic. In another 12 months this will be worth significantly more. I'm happy to wait and accumulate but if offers appear, given previous investor support, I'm also interested.

[luzley] 25/3/2024 11:41

At £22m MCap the rapidly escalating feedback from consultants and global hospitals is that Steriwave is quick simple and effective. To reduce hospital acquired infections by around 75% is truly gamechanging however you look at it. This is a hugely significant fact given the lack of any new antibiotics and need to keep at least one or two for global emergencies. A big player just has to take this out and the CEO with a major shareholding must have an exotic strategy. The time is now.

[marvelman] 25/3/2024 11:12

Zico..Great news today in particular. However, I am well aware why we are not at 12p plus and it it is clearly not the business model. It is funding. I am still in here quite well invested albeit apprehensively but on balance rather be in than out with so much upside possibility.

[jailbird] 25/3/2024 08:34

NCAgree with 9p placing holders looking slice at a profit and now funding price to be agreed to next placing , I would rather wait There is plenty of time to get in as the story unfolds At the moment the company needs a lot of cash to build contracts and revenues . It is using up cash fast still Just hope this is the last placing this time

[jailbird] 25/3/2024 08:31

Luzley A bit naive to say that considering the share price had fallen 60% from 18p+ , as the market knew a placing was coming To say it was at a premium is laughable

[tidy 2] 25/3/2024 08:29

The Security of NHS contracts will not be an issue there.

[babbler] 25/3/2024 08:23

There was a placing in December

[nchanning] 25/3/2024 08:15

28 million CAD loss forecast just for this year , really need a very large placing to give some breathing room . In a good market this would be 150m market cap and the dilution wouldn't be that severe but AIM very tough market to fund a growth company in right now

[luzley] 25/3/2024 08:13

Last placing was at a premium. Main shareholder is CEO who holds loads and is 60+. This is a prime t/o target now for the likes of Stryker,S&N, Halma imo. Solid progress that could go exponential with global uptake as huge cost benefits are seen.

[purple11] 25/3/2024 08:04

whos to say it will be at a discount.the last one was done at a premium

[nchanning] 25/3/2024 07:57

Not sure how I can buy this when there must be a huge discounted placing coming . Great tech , would be delighted to buy once refinanced

[luzley] 25/3/2024 07:49

The ongoing gamechanger is that the last NHS related news was in oropharyngeal surgery where nasal bacteria and viruses are in the nasal region. This adoption is in orthopaedics....that is highly significant and has been trialed and proven to massively reduce post operative infection. HAI's cost the NHS a fortune and this potentially opens the door to widespread pre-op Steriwave use across all NHS ops. Huge opportunity and validated.

[jailbird] 25/3/2024 07:40

Excellent news So far this year .

[z1co] 25/3/2024 07:19

After this first deals , i expect many more and Steriwave will most definitely take off in the UK like it has Canada.

Not so good if you've sold and were deramping last week!!!

[z1co] 25/3/2024 07:14

Excellent news:

25 March 2024

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

First commercial adoption of Steriwave by the NHS

NHS deal gives patients access to groundbreaking light-activated antimicrobial to combat AMR (antimicrobial resistance)

· A new light-activated antimicrobial that kills all types of bugs - viruses, bacteria, and fungi - in minutes without generating resistance is being adopted by two NHS hospitals to reduce surgical infections.

Mid Yorkshire Teaching NHS Trust has approved the commercial adoption of Ondine's groundbreaking light-activated antimicrobial, Steriwave®. The approval will see the use of Steriwave expanded across hip and knee surgery patients at Pontefract and Pinderfields NHS Hospitals to reduce the incidence of surgical site infections (SSIs). This adoption as standard-of-care for orthopedic patients follows a successful, initial deployment that is being used to evaluate Steriwave at Pontefract Hospital.

Dr Stuart Bond, Consultant antimicrobial pharmacist and Director of Innovation at Mid Yorkshire Teaching NHS Trust, commented:

"We are very pleased to be the first NHS Trust to be giving patients access to this important new technology. SSIs can have a devastating effect on patients and their families, and we are pleased that we have demonstrated the feasibility of using Steriwave in our Orthopaedic Centre of Excellence at Pontefract Hospital. It is a real step forward to making Steriwave more widely available across the Trust."

[bamboo2] 25/3/2024 07:13

Expansion planned.

================


The full findings of this study [are expected to be reported on later this year and] will be used to support the further spread and adoption of Steriwave across the NHS and across additional surgical applications.

[bamboo2] 25/3/2024 07:11

First commercial adoption of Steriwave by the NHS

NHS deal gives patients access to groundbreaking light-activated antimicrobial to combat AMR (antimicrobial resistance)

· A new light-activated antimicrobial that kills all types of bugs - viruses, bacteria, and fungi - in minutes without generating resistance is being adopted by two NHS hospitals to reduce surgical infections.

Mid Yorkshire Teaching NHS Trust has approved the commercial adoption of Ondine's groundbreaking light-activated antimicrobial, Steriwave®. The approval will see the use of Steriwave expanded across hip and knee surgery patients at Pontefract and Pinderfields NHS Hospitals to reduce the incidence of surgical site infections (SSIs). This adoption as standard-of-care for orthopedic patients follows a successful, initial deployment that is being used to evaluate Steriwave at Pontefract Hospital.

Dr Stuart Bond, Consultant antimicrobial pharmacist and Director of Innovation at Mid Yorkshire Teaching NHS Trust, commented:

"We are very pleased to be the first NHS Trust to be giving patients access to this important new technology. SSIs can have a devastating effect on patients and their families, and we are pleased that we have demonstrated the feasibility of using Steriwave in our Orthopaedic Centre of Excellence at Pontefract Hospital. It is a real step forward to making Steriwave more widely available across the Trust."

The CEO of Ondine Biomedical, a world leader in light-activated antimicrobial technology, Carolyn Cross, said:

"We are delighted to see the first two NHS hospitals adopt Steriwave, particularly as NHS is seen around the world as a leader in antibiotic stewardship in response to the growing threat of AMR (antimicrobial resistance). This is not only a significant milestone for Ondine, but Mid Yorks's accelerated decision to adopt suggests that Steriwave has been well received by patients, surgeons, and nurses."

As announced on 5 March 2024, Ondine Biomedical, Mid Yorkshire Teaching NHS Trust, and Health Innovation Yorkshire & Humber have partnered to sponsor a health economic analysis with the York Health Economics Consortium (YHEC). The full findings of this study [are expected to be reported on later this year and] will be used to support the further spread and adoption of Steriwave across the NHS and across additional surgical applications.

SSIs are one of the most common healthcare-associated infections (HAIs) and affect one in every 20 patients who undergo a surgical procedure in the NHS.[1] SSIs can cost up to £100,000 per patient,[2] and the overall cost of HAIs to NHS England is over £2 billion a year.[3] These costs are expected to rise as growing rates of antimicrobial resistance (AMR) make the current standard of care - the antibiotic mupirocin - less effective.[4]

Steriwave is a light-activated antimicrobial that uses a specific wavelength of red light to destroy pathogens that colonise the nose and can spread to cause harmful infections. Crucially, unlike traditional antibiotics, Steriwave is immediately effective with a single five-minute treatment and does not trigger antimicrobial resistance (AMR). Nasal decolonization - eliminating harmful pathogens from the nasal cavities - is recommended by WHO and NICE prior to surgery as a key approach to preventing SSIs.[5]

Steriwave has been used in over 150,000 patient treatments, including at major hospitals across Canada, including Vancouver General Hospital (VGH), The Ottawa Hospital (TOH), and the Mazankowski Alberta Heart Institute. Research recently published by VGH in the Canadian Journal of Surgery showed that the use of Steriwave in patients undergoing spine surgery resulted in a 66.5% reduction in post-surgical infection rates and almost $2600 per spine surgery patient, representing $2.5 million in annual savings for Vancouver General Hospital's spine group.[6] No serious adverse events have ever been reported from Steriwave treatment.

[jailbird] 22/3/2024 20:44

Luzley,

Phase 3 - non-dilutive funding opportunities and numerous AMR-related government initiatives.

but for near term funding - it will be dilution again from last RNS

[luzley] 21/3/2024 16:03

Ondine has specifically addressed any need for funding in its last interim. This was prior to the investor-led financing at 9p - a premium to the shareprice at the time. The CEO quotes:The rise of antimicrobial resistance ("AMR") is driving governments and research institutes to seek new solutions to combat antimicrobial-resistant pathogens and help prevent millions of deaths. Because of the demonstration of efficacy against ESKAPE and extremely drug-resistant pathogens of major concern to global health authorities, we are accelerating our pursuit of non-dilutive funding opportunities and numerous AMR-related government initiatives.Multiple agencies have consistently identified a select group of pathogens (i.e., the ESKAPE pathogens) responsible for the majority of HAIs. Many of the same microorganisms are notorious for their tenacity, pathogenicity, virulence, proclivity for resistance and ultimately, the severity of their infections.

[luzley] 21/3/2024 15:35

Jumped up on volume but drifted back a little on drips and draws. Expect next move north as tech is proving expansive and sticky now. Word of mouth between consultants and health trusts are becoming the new driver. Good news on reducing cost burdens is the key. I'm patient here. The horizon is so bright in this desperate-for-a-solution antibiotic war that funding if needed should be no problem at the current price. CEO has loads of skin in the game and I actually suspect that the recent CFO appointment is related to her exit strategy in the near future.